



Reporter Cell Lines

The family keeps growing

[Learn more >](#)

InVivoGen



A Pegylated Derivative of α -Galactosylceramide Exhibits Improved Biological Properties

This information is current as of April 23, 2019.

Thomas Ebensen, Claudia Link, Peggy Riese, Kai Schulze, Michael Morr and Carlos A. Guzmán

J Immunol 2007; 179:2065-2073; ;
doi: 10.4049/jimmunol.179.4.2065
<http://www.jimmunol.org/content/179/4/2065>

References This article **cites 55 articles**, 19 of which you can access for free at:
<http://www.jimmunol.org/content/179/4/2065.full#ref-list-1>

Why *The JI*? [Submit online.](#)

- **Rapid Reviews! 30 days*** from submission to initial decision
- **No Triage!** Every submission reviewed by practicing scientists
- **Fast Publication!** 4 weeks from acceptance to publication

**average*

Subscription Information about subscribing to *The Journal of Immunology* is online at:
<http://jimmunol.org/subscription>

Permissions Submit copyright permission requests at:
<http://www.aai.org/About/Publications/JI/copyright.html>

Email Alerts Receive free email-alerts when new articles cite this article. Sign up at:
<http://jimmunol.org/alerts>



A Pegylated Derivative of α -Galactosylceramide Exhibits Improved Biological Properties

Thomas Ebensen,¹ Claudia Link,¹ Peggy Riese, Kai Schulze, Michael Morr, and Carlos A. Guzmán²

The glycolipid α -galactosylceramide (α GalCer) has immunomodulatory properties, which have been exploited to combat cancer, chronic inflammatory diseases, and infections. However, its poor solubility makes α GalCer a suboptimal compound for in vivo applications. In this study, a pegylated derivative of α GalCer is characterized, which exhibits improved physical and biological properties. The new compound, α GalCerMPEG, is water-soluble and retains the specificity for the CD1d receptor of α GalCer. The in vitro stimulatory properties on immune cells (e.g., dendritic cells and splenocytes) are maintained intact, even when tested at a 33-fold lower concentration of the active moiety than α GalCer. NK cells isolated from mice treated with α GalCerMPEG also had stronger cytotoxic activity on YAC-1 cells than those obtained from animals receiving either α GalCer or CpG. Intranasal immunization studies performed in mice showed that α GalCerMPEG exerts stronger adjuvant activities than the parental compound α GalCer when tested at 0.35 vs 11.7 nM/dose. Coadministration of β -galactosidase with α GalCerMPEG resulted not only in high titers of Ag-specific Abs in serum (i.e., 1:512,000), but also in the stimulation of stronger Th2 and secretory IgA responses, both at local and remote mucosal effector sites (i.e., nose, lung, and vagina). The new synthetic derivative α GalCerMPEG represents a promising tool for the development of immune interventions against infectious and noninfectious diseases. *The Journal of Immunology*, 2007, 179: 2065–2073.

Most pathogens enter the host via the mucosal membranes. Therefore, the induction of systemic and mucosal immune responses following immunization represents a major goal in vaccine development. Vaccines delivered through mucosal surfaces induce not only systemic but also mucosal immune responses and trigger efficient immunological memory (1–6). In addition, this approach is associated with easier and less expensive administration logistics, being particularly suitable for mass vaccination. However, to implement this strategy, several hurdles should be overcome. The most important bottleneck is the poor immunogenicity of purified Ags administered by this route. This is in part due to their mechanical clearance, enzymatic degradation, and structural modification (e.g., by extreme pH), as well as to the fact that mucosal territories represent tolerance-prone niches.

To improve the immunogenicity of vaccine Ags, they can be coadministered with mucosal adjuvants. Unfortunately, the development of efficient and safe adjuvants still remains a challenge for the vaccine industry. Nevertheless, recent advances in our understanding of the immune system, in particular regarding early proinflammatory signals, have led to the identification of promising molecular targets for screening programs aimed at the discovery of compounds with immunomodulatory properties (7–12). Improved

biochemical techniques also allow full synthesis of well-defined molecules.

The glycolipid α -galactosylceramide (α GalCer),³ originally derived from the marine sponges *Agelas mauritianus*, exhibits potent antitumor activity (13). This compound also has immune modulatory properties, leading to the activation of various cell subsets of the innate and adaptive immune system. It was shown that α GalCer is presented by CD1d molecules on APCs, acting as a ligand for invariant V α 14⁺ NKT cells (14), which produce large amounts of IFN- γ and IL-4 upon α GalCer activation (15–20). The immune modulatory properties of α GalCer have been exploited to enhance responses against viral and parasitic Ags after vaccination (21–25). A recent study also suggested that α GalCer can act as mucosal adjuvant (1). However, there are major drawbacks preventing an efficient transfer of α GalCer into the clinical development pipeline, such as its poor solubility. To provide soluble formulations, nonorganic solvents or detergents are needed, which represent a safety concern and might affect the immunological properties of some Ags.

An efficient and safe method to improve the solubility of chemical compounds in aqueous solutions is their conjugation with polyethylene glycol (PEG). The process of pegylation can also improve their half-life by shielding, as well as by reduction of both metabolic degradation and receptor-mediated endocytosis (26–28). Of particular relevance for vaccine development is the fact that PEG is nontoxic and very poorly immunogenic (29–35). Therefore, in the present work, we evaluated whether conjugation to PEG can improve the immune modulatory properties of

Department of Vaccinology, Helmholtz Centre for Infection Research, Braunschweig, Germany

Received for publication September 22, 2006. Accepted for publication May 29, 2007.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked *advertisement* in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

¹ T.E. and C.L. equally contributed to the work.

² Address correspondence and reprint requests to Dr. Carlos A. Guzmán, Department of Vaccinology, Helmholtz Centre for Infection Research, Inhoffenstrasse 7, D-38124 Braunschweig, Germany. E-mail address: cag@helmholtz-hzi.de

³ Abbreviations used in this paper: α GalCer, α -galactosylceramide; PEG, polyethylene glycol; DC, dendritic cell; i.n., intranasal; β -Gal, β -galactosidase; α GalCerMPEG, pegylated derivative of α GalCer; ANS, 1-anilino-8-naphthalenesulfonate; BAL, bronchial alveolar lavage; NL, nasal lavage; MFI, mean fluorescence intensity; sIgA, secretory IgA.

Copyright © 2007 by The American Association of Immunologists, Inc. 0022-1767/07/\$2.00

α GalCer. The obtained results have demonstrated that the new PEGylated derivative of α GalCer (α GalCerMPEG) is able to activate in vitro primary cultures of murine dendritic cells (DC) and NKT cells more efficiently than α GalCer, even when tested at a 33-fold lower concentration of the active moiety. Intranasal (i.n.) coadministration of β -galactosidase (β -Gal) with α GalCerMPEG stimulated similar immune responses in mice to those observed using α GalCer, but using 33-times less compound (i.e., 0.35 and 11.7 nM/dose, respectively). Interestingly, α GalCerMPEG was a superior inducer of secretory (sIgA) and Th2 responses than the parental compound α GalCer.

Materials and Methods

Synthesis of α GalCerMPEG

To render α GalCer soluble in aqueous solvents a pegylated derivative was generated which was prepared using a modification of the protocol from Zhou et al. (36). In brief, methyl-PEG-COOH was dissolved in dichloromethane, mixed with hydroxybenzotriazole and 1 di-isopropylcarbodiimide, and added to a solution of α GalCer (Fig. 1A) in dichloromethane. The resulting mixture was incubated under stirring in the absence of humidity for 15 h at room temperature to generate an intermediate compound (Fig. 1B), which was purified by silica gel chromatography using chloroform and chloroform/methanol, dissolved in ethyl acetate/methanol (1:1), and hydrogenated using palladium/charcoals as catalyst for 9 h at 40°C. The resulting hydrogenated compound (i.e., α GalCerMPEG, Fig. 1C) was finally purified by silica gel chromatography using a mixture of chloroform and methanol. The purity of α GalCerMPEG was analyzed by reverse-phase HPLC (Waters Alliance) using a LUNA column (Phenyl-Hexyl-phase; C18; 4.6 \times 50 mm; 3 μ m; Phenomenex) and evaporative light scattering detection (ELSD Waters; detection limit 0.01%). As shown in Fig. 1D, the HPLC analysis (37) demonstrated that the resulting compound exhibits a high degree of purity (96%). The structure of the α GalCerMPEG was confirmed by matrix-assisted laser desorption/ionization mass spectrometry (Table I). 1 H- and 13 C-spectra, which showed a shift referenced to the residual signal of CHCl_3 at 7.25 ppm and CD_3OD at 49 ppm, were recorded at 300°K on a Bruker AVANCE DMX600 NMR spectrometer locked to the major deuterium signal of the solvent. Samples were dissolved in CDCl_3 and a 4:1 mixture of CDCl_3 to CD_3OD , respectively.

Determination of the solubility in water of α GalCerMPEG

Comparative studies were performed to analyze the solubility in water of α GalCerMPEG with respect to the parenteral compound α GalCer. In addition to the conventional measurements, the fluorescence dye I-anilino-8-naphthalenesulfonate (ANS) magnesium salt (Sigma-Aldrich) was also used. To this end, probes were dissolved in water containing ANS, according to established protocols (38). In brief, changes in fluorescence parameters and induced circular dichroism spectra at 360 nm indicate conformational changes resulting from ANS binding to the soluble form of each compound (39).

Preparation and flow cytometric analysis of murine DC

Bone marrow-derived primary DC were prepared from BALB/c mice using recombinant murine GM-CSF (BD Pharmingen), as previously described (40). On day 5, DC were cocultured with α GalCerMPEG (1.7 pM), α GalCer (58 pM), or 56.3 pM MPEG (data not shown) for 40 h. Control cells were treated with LPS from *Salmonella enterica* serovar typhimurium (Sigma-Aldrich) at a final concentration of 1 μ g/ml. For flow cytometry, cells were preblocked using anti-mouse CD32/16 Ab for 15 min. Then, DC were stained with FITC-labeled Abs against mouse MHC class I (SF1-1.1), MHC class II (AMS-32.1), CD80 (16-10A1), CD86 (GL1), CD40 (3/23), CD54 (3E2) or CD11d (1B1), together with PE-labeled Ab against CD11c (HL3) (BD Pharmingen). As negative controls, FITC- or PE-conjugated isotype control Abs were used. The FACS analysis of 20,000 events was performed using a FACSsort and the CellQuest software (BD Biosciences), gating on CD11c-positive cells. Results are expressed as percentages of the total number (i.e., 50,000) of viable gated CD11c⁺ cells (%) and as geometric mean fluorescence intensity (MFI). Results correspond to one representative experiment of five independent tests.

Measurement of cellular proliferation

To analyze the in vitro activity of α GalCerMPEG on cellular proliferation, splenocytes (5 \times 10⁵ cells/well) of female BALB/c (H-2^d; Harlan Winkel-




FIGURE 1. Synthesis of α GalCerMPEG. The parental compound α GalCer (A) was mixed with methyl-PEG-COOH (R-PEG-COOH) in the presence of hydroxybenzotriazole (HOBt) and 1 di-isopropylcarbodiimide (DIC). This led to an intermediate compound (B), which was purified and hydrogenated using palladium/active charcoals (Pd/A) as catalyst. The resulting α GalCerMPEG (C) was purified by silica gel chromatography, and its purity was analyzed by reverse-phase HPLC using a LUNA column and evaporative light scattering detection. The peak corresponding to the final product is indicated by an arrow (D).

mann) or CD11d^{-/-} (The Jackson Laboratory) mice of 6 wk of age were incubated in triplicates with either α GalCerMPEG (0.35 nM), α GalCer (11.7 nM), DMSO, or sterile water (Ampuwa) for 48, 72, or 96 h. Then, cellular proliferation was determined by measuring the incorporation of [³H]thymidine using a scintillation counter (Wallac 1450; MicroTrilux), as previously described (41).

Cytotoxicity assay

Mice received α GalCer (11.7 nM) or α GalCerMPEG (0.35 nM) by i.n. route, whereas control animals were injected by i.p. route with CpG (100 μ g; i.e., 2.25 nM). After 2 days, animals were sacrificed and their splenocytes

Table I. α GalCerMPEG analysis in CDC13/CD3OD (4/1 v/v) by ^1H and ^{13}C -NMR

^1H -NMR			^{13}C -NMR	
Moiety	Shifts (56)	J (Hz)	Moiety	Shifts multiplicity
α Galactopyranosyl			α Galactopyranosyl	
H-1	4.68	(1-2) 3.8	C-1	100.0, d
H-2	3.59		C-2	^a
H-3	3.53-3.40		C-3	^a
H-4	3.53-3.40		C-4	^a
H-5	3.59		C-5	69.2, d
H-6A	3.36		C-6	40.0, t
H-6B	3.05	(5-6B) 7.1	PhCH2 a/b/c	
6-NH		(6A-6B)13.8	PhCH2 i/o/m/p	
Ceramide			Ceramide	
H-1A	3.66	(1A-1B)10.6	C-1	67.6, t
H-1B	3.46	(1A-2) 4.9	C-2	50.7, d
H-2	4.00		C-3	75.1, d
2-NH			C-4	^a
H-3	3.35		C-5	33.0, t
H-4	3.37		C-6	26.1, t
H-5A	1.47		C-1'	174.8, s
H-5B	1.19		C-2'	36.7, t
H-2' AB	2.01		C-3'	26.1, t
H-3'	1.41		(CH2)n	30.1-29.6, t
(CH2)n	1.17		CH2	32.1, t
CH3	0.69		CH2	22.9, t
			CH3	14.1, q
MPEG			MPEG	
H-2	2.30		C-1	174.1, s
H-3	2.30		C-2	31.5, t
5-NH			C-3	31.5, t
H-6	3.20		C-4	173.3, s
H-7	3.36		C-6	39.5, t
OCH2CH2O	3.47		C-7	69.9, t
OCH3	3.20		(OCH2CH2)n	70.6, t
			OCH2CH2	70.3/72.0, t
			OCH3	59.0, t

^a Signals at 69.2, 69.4, 70.3, and 72.4 ppm ($4 \times d$).

were used as effector cells in a standard ^{51}Cr -release assay using YAC-1 cells as targets for NK cells. Effector cells were washed and their concentration was adjusted to $1 \times 10^6/\text{ml}$. In parallel, target cells were incubated in RPMI 1640 medium (Invitrogen Life Technologies) without FCS containing 100 μCi of ^{51}Cr for 2 h. Then, target cells were extensively washed with RPMI 1640 medium containing FCS and coincubated in triplicates with effector cells at different E:T ratios. After 4 h, cells were centrifuged and the radioactivity present in supernatants was measured by scintillation counting. Maximal lysis was determined after lysis with 5% Triton X-100, whereas spontaneous lysis was measured in supernatants of untreated target cells. Results are expressed as percentage of lysed cells, accordingly to the formula: (sample - spontaneous lysis)/(maximal lysis - spontaneous lysis) \times 100.

Immunization protocols

Groups of female BALB/c (H-2^d) mice ($n = 5$) of 6-8 wk of age were immunized by i.n. route on days 0, 14, and 28 with 30 μg of the β -Gal protein (Roche) alone or coadministered with either α GalCer or α GalCerMPEG (11.7 and 0.35 nM active moiety/dose/animal, respectively). The optimal amount of the adjuvants used were experimentally determined in preliminary studies. Animals in the negative control group received only PBS. The animal permission was given by the local government of Lower Saxony (No. 509.42502/07-04.01).

Sample collection

Serum samples were collected on days -1, 13, 27, and 42. On day 42, mice were sacrificed, spleens were removed, and nasal (NL), bronchoalveolar (BAL), and vaginal (42) lavages were obtained by flushing the organs with PBS supplemented with 50 mM EDTA, 0.1% BSA, and 10 mM PMSF. For collecting the BAL, a catheter was inserted into the trachea after tracheotomy, whereas NL samples were obtained by gently flushing the nasal cavities from the posterior opening of the nose after removing the mandible. Lavages were then centrifuged to remove debris (10 min at $3000 \times g$) and supernatant fluids were stored at -20°C until processing. Abs were

examined by investigating individual animals, whereas cellular responses were analyzed using pools of spleen cells, as previously described (43).

Detection of anti- β -Gal IgG in serum

The presence of β -Gal-specific serum Abs was determined by ELISA using microtiter plates coated with 100 μl /well of β -Gal (2 $\mu\text{g}/\text{ml}$ in 0.05 M carbonate buffer (pH 9.6)), as previously described (43). β -Gal-specific IgG subclasses present in sera were measured using an isotype-specific ELISA. Endpoint titers were expressed as the reciprocal of the last dilution, which gave an OD at 405 nm of 0.1 U above the values of the negative controls after 15 min of incubation.

Determination of total and anti- β -Gal IgA

The amount of total and β -Gal-specific IgA present in the lavages was determined by ELISA, as previously described (41). To compensate for variations in the efficiency of recovery of secretory Abs among animals, the results were normalized and expressed as endpoint titers of Ag-specific IgA per microgram of total IgA present in the sample.

ELISPOT assay

To determine the amount of IFN- γ -, IL-2-, and IL-4-secreting cells, ELISPOT kits for the detection of murine IFN- γ , IL-2, and IL-4 (BD Pharmingen) were used. Spleen cells (1×10^6 and $5 \times 10^5/\text{well}$) were incubated for 24 h (IFN- γ) or 48 h (IL-2 and IL-4) in the absence or presence of a β -Gal peptide (TPHARIGL) encompassing a MHC class I-restricted epitope (for IFN- γ) or the β -Gal protein (for IL-2 and IL-4), at a concentration of 10 μM . Then, cells were removed and the plates processed according to the manufacturer's instructions. Colored spots were counted with a CTL ELISPOT reader and analyzed using the ImmunoSpot image analyzer software version 3.2.

Cytometric bead array

For the characterization of the cytokines secreted by splenocytes of vaccinated animals restimulated *in vitro* with the β -Gal protein, supernatants were collected on days 2 and 4, and stored at -70°C until the content of IFN- γ , TNF- α , IL-2, and IL-10 was determined using the cytometric bead array (BD Pharmingen) by flow cytometry, according to the manufacturer's instructions.

Statistic analysis

The statistic significance of the differences observed between the different experimental groups was analyzed using the Student unpaired *t* test and the nonparametric Mann-Whitney *U* test. Differences were considered significant at $p < 0.05$.

Results

α GalCerMPEG exhibits stronger stimulatory activity on bone marrow-derived DC and splenocytes than α GalCer

To characterize the functional properties of the water soluble derivative α GalCerMPEG, a side-by-side comparative analysis of its biological activities with respect to those of the parental compound α GalCer was conducted. First, we compared the solubility in water of α GalCerMPEG with respect to the parenteral compound α GalCer. As expected, the hydrophobic parental compound α GalCer was completely insoluble in water, being essential the addition of DMSO to render it soluble. In contrast, the pegylated derivative was soluble in water up to a concentration of at least 100 mg/ml. Additional studies were performed to evaluate the fluorescence of the α GalCer/ANS complexes. The hydrophobic parental compound α GalCer was insoluble in water (i.e., no changes in the spectra due to the lack of binding to ANS), whereas an enhanced fluorescence resulting from the generation of α GalCerMPEG/ANS complexes was observed in the aqueous phase when the pegylated derivative was tested (data not shown).

Then, the effect of α GalCerMPEG on the activation and maturation of bone marrow-derived murine DC was assessed. As shown in Fig. 2 and Table II, α GalCerMPEG (1.7 pM active moiety/well) promotes an efficient activation and maturation of DC *in vitro*, as demonstrated by the up-regulated expression of MHC class II, costimulatory (CD80, CD86) and adhesion (CD40, CD54) molecules. The expression of the surface receptor for the α GalCer moiety, CD1d, was also enhanced on α GalCerMPEG-treated DC. In contrast, there was only a weak stimulation of the activation markers when DCs were stimulated using a 33-fold higher concentration of the parental compound α GalCer (58 pM/well), both in terms of MFI and percentage of positive cells (Fig. 2).

The *in vitro* capacity of α GalCerMPEG to stimulate the proliferation of splenocytes and its dependency on the expression of the CD1d receptor were then investigated. To this end, splenocytes of naive BALB/c and CD1d $^{-/-}$ mice were stimulated with either α GalCer or α GalCerMPEG. A time-dependent stimulation of cellular proliferation was observed in cells treated with α GalCerMPEG (Fig. 3A). The response was significantly stronger than the one observed when splenocytes were treated with a 33-fold excess of α GalCer ($p < 0.05$). As expected, the stimulation was dependent on the expression of the CD1d molecule, as demonstrated by the lack of any effect when spleen cells from CD1d $^{-/-}$ mice were used.

Next, the effect of α GalCerMPEG on the cytotoxic activity of NK cells was investigated. Similar responses were observed using control cells from mice stimulated *in vivo* with α GalCer (11.7 nM) or CpG (2.25 nM), namely 37–36% and 34–27% at E:T ratios of 100:1 and 50:1, respectively. In contrast, when animals received a 33-fold lower dose of the α GalCerMPEG active moiety (0.35 nM), an even stronger response was observed (46–56% lysis; see Fig. 3B). α GalCerMPEG was stable and active for at least 2 mo at room




FIGURE 2. Activation and maturation of murine DC by α GalCerMPEG. The expression of surface markers was investigated by flow cytometry on CD11c $^{+}$ -gated bone marrow-derived murine DC before (shaded area) and after stimulation with either 1.7 pM α GalCerMPEG (continuous line) or 58 pM α GalCer (broken line). One representative experiment of three is shown.

temperature and 4°C , as shown by the intact ability to stimulate the proliferation of spleen cells (data not shown).

α GalCerMPEG promotes the elicitation of efficient humoral immune responses when coadministered with an Ag by *i.n.* route

To evaluate the adjuvant properties of the pegylated derivative of α GalCer, mice were immunized by *i.n.* route with β -Gal (30 μg /dose) alone or coadministered with either α GalCer (11.7 nM/dose) or α GalCerMPEG (0.35 nmol/dose). Similar humoral responses were observed in sera from animals vaccinated with α GalCerMPEG and α GalCer as adjuvant, with high Ab titers even after a single boost (Fig. 4A). In contrast, very weak responses were detected in control animals receiving β -Gal alone. This demonstrated that the pegylated derivative is able to stimulate strong humoral responses also when used at a 33-fold lower concentration than α GalCer.

Then, the capacity of the two compounds to stimulate mucosal immune responses was investigated. To this end, β -Gal-specific sIgA was measured in NL, BAL, and VL from vaccinated animals (Fig. 4B). Immunization with α GalCerMPEG by the *i.n.* route resulted in the induction of significantly stronger β -Gal-specific sIgA responses in all tested mucosal territories than those observed in mice receiving β -Gal alone ($p < 0.05$). In contrast, in mice receiving β -Gal and α GalCer at a 33-fold higher concentration, the

Table II. Results are expressed in percentages of the total number (i.e., 50,000) of viable gated CD11c⁺ cells (%) and as geometric MFI^a

Marker	Control		αGalCer (58 pM/ Well Active Moiety)		αGalCerMPEG (1.7 pM/Well Active Moiety)	
	%	MFI	%	MFI	%	MFI
CD40	22	9.5	18	8.6	47	17.5
CD54	37	54.1	41	60.1	78	129.5
CD80	14	42.3	15	44.9	41	83.4
CD80	21	27.4	21	29.3	42	41.1
MHC class I	18	116.8	21	129.7	22	139.1
MHC class II	29	162.6	34	168	49	199.4
CD1d	17	13.9	18	15.1	22	21.7

^a One representative experiment of three independent tests is shown.

differences were statistically significant with respect to the β-Gal-vaccinated control group only in BAL.

The use of αGalCerMPEG as mucosal adjuvant results in the stimulation of a dominant Th2 response

First, the subclass distribution of β-Gal-specific serum IgG was determined to evaluate the major Th response pattern stimulated in vaccinated mice. A significant increment on β-Gal-specific IgG1 was observed in mice receiving either αGalCerMPEG or αGalCer as adjuvants, whereas IgG2a was increased to a significant minor extent (Fig. 5A). This demonstrates that αGalCerMPEG promotes a Th2-type response, suggesting also that pegylation does not affect the immune modulatory properties of the active αGalCer moiety.

To further characterize the Th responses, the number of β-Gal-specific IFN-γ-, IL-2-, and IL-4-secreting cells present in spleens of vaccinated mice was determined by ELISPOT. In agreement to what was observed for the IgG isotypes, high numbers of IL-4-secreting cells were detected in mice receiving αGalCerMPEG or αGalCer (Fig. 5B). In contrast, the number of IFN-γ- and IL-2-secreting cells was increased to a significant minor extent in response to stimulation with the MHC class I-restricted peptide and the β-Gal protein, respectively. Thus, cytometric bead array studies were performed with supernatants from restimulated splenocytes to confirm the secretion of Th1 cytokines. The obtained results showed that IFN-γ and IL-2 were indeed secreted by spleen cells from vaccinated mice in which αGalCer or αGalCerMPEG were coadministered ($p < 0.05$) in comparison to those from

FIGURE 3. Comparative analysis of the stimulatory activities of αGalCerMPEG and αGalCer. *A*, Spleen cells from CD1d^{-/-} and BALB/c mice were stimulated in vitro with αGalCer (11.7 nM active moiety) and αGalCerMPEG (0.35 nM active moiety) for 48, 72, and 96 h. Cellular proliferation was assessed by determination of the [³H]thymidine incorporated into the DNA of replicating cells. Results are averages of triplicates and they are expressed as cpm. SEM is indicated by the vertical lines. One representative of four independent experiments is shown. *B*, In vivo stimulation of lytic activity by αGalCerMPEG. Spleen cells from mice injected with αGalCer (11.7 nM), αGalCerMPEG (0.35 nM), or CpG (2.25 nM) were recovered after 48 h and used as effectors in a ⁵¹Cr-release assay with YAC-1 cell targets. The results are expressed as percentage of lysis and they are average of triplicates. One representative of three independent experiments is shown. *, The values were significantly ($p < 0.05$) different with respect to those from control cells (untreated and DMSO treated). ○, Significantly ($p < 0.05$) different values with respect to results obtained with αGalCer-treated cells.





FIGURE 4. Humoral immune responses stimulated in mice vaccinated using α GalCerMPEG as adjuvant. **A**, Kinetic analysis of anti- β -Gal IgG responses in sera from mice ($n = 5$) immunized on days 1, 14, and 28 (indicated by arrows) with PBS (controls), β -Gal (30 μ g/dose), β -Gal + α GalCer (11.7 nM/dose), or β -Gal + α GalCerMPEG (0.35 nM/dose) by the i.n. route. Results are expressed as the mean end point titers; SEM is indicated by vertical lines. One representative of three independent experiments is shown. **B**, Stimulation of sIgA responses in mice immunized using α GalCerMPEG as adjuvant. The presence of β -Gal-specific sIgA was investigated in NL, BAL, and VL by ELISA. Results are expressed as mean β -Gal-specific sIgA titers with respect to 1 μ g of total sIgA. SEM is indicated by vertical lines. One representative of three independent experiments is shown. *, The obtained results were significantly different ($p < 0.05$) with respect to those from animals immunized with PBS or β -Gal alone. \circ , Significantly ($p < 0.05$) different values with respect to results obtained in mice immunized with β -Gal + α GalCer.



animals receiving β -Gal alone (Fig. 5C). The concentrations of the Th1 cytokines, such as IFN- γ or IL-2, secreted by cells recovered from mice vaccinated with α GalCerMPEG were significantly ($p < 0.05$) lower than those observed in animals receiving α GalCer (Fig. 5C). This suggested the induction of more strongly polarized Th2-like response when the pegylated derivative of α GalCer was used. The secretion of the proinflammatory cytokine IL-6 was similar when splenocytes recovered from mice immunized with either α GalCerMPEG or the parental compound were tested ($p > 0.05$). In contrast, the secretion of TNF- α was significantly higher in cells from animals immunized with β -Gal plus α GalCer with respect to cells from mice receiving β -Gal plus α GalCerMPEG ($p < 0.05$). Interestingly, significantly ($p < 0.05$) higher levels of the anti-inflammatory cytokine IL-10 were secreted by cells derived from mice receiving α GalCerMPEG (Fig. 5C). This might hint to a better pharmacological profile for the pegylated derivative.

Discussion


Experimental studies have shown that α GalCer has strong immunomodulatory properties, which can be exploited to prevent tumor metastases, modulate autoimmunity, and improve the clearance of microbial pathogens (44). Additional work has demonstrated that α GalCer exhibits adjuvant properties that can be used for vaccine development (23, 25). More recently, it was established that the adjuvant properties of α GalCer are also exerted after mucosal administration (45). In fact, mice vaccinated by the i.n. route using α GalCer as adjuvant were protected against a viral infection or a

challenge with tumor cells in experimental models. Encouraging results are also emerging from clinical trials performed in cancer patients, in which α GalCer has been used as immune therapeutic (42, 46–48).

Despite these promising results, the physicochemical properties of α GalCer are suboptimal for in vivo use. The chemical structure renders α GalCer completely insoluble in aqueous solutions, making necessary the preparation of stocks in nonorganic solvents or in the presence of detergents. This not only represents a safety concern, but it might in turn affect the immunological properties of some Ags. Recent studies have also showed that derivatization of α GalCer can lead to compounds with novel biological properties. For example, α -C-GalCer shows a more stable binding to DC (15). Previous pharmacological studies have shown that pegylation cannot only render a molecule soluble in water, but also increase its half-life by reducing metabolic degradation and clearance (26–28). In contrast, the poor immunogenicity of PEG renders it an ideal conjugation partner, particularly for a compound to be used as immunomodulator such as α GalCer (29–35). Thus, we decided to evaluate whether pegylation might indeed improve the physical and/or biological properties of α GalCer. To this end, a pegylated derivative of α GalCer was generated and characterized both in vitro and in vivo.

The obtained results demonstrated that the pegylated derivative of α GalCer is completely soluble in water. The new compound, α GalCerMPEG, also exhibits an enhanced capacity to activate bone marrow-derived murine DC with respect to α GalCer, even at a 33-fold lower concentration (see Fig. 2 and Table I). This is a

FIGURE 5. Analysis of the Th responses stimulated in mice vaccinated using α GalCerMPEG as adjuvant. *A*, Determination of the β -Gal-specific IgG isotypes present in sera. Results are expressed as mean end point titers. One representative of four independent experiments is shown. *B*, Detection of IFN- γ , IL-2-, and IL-4-secreting cells in immunized mice. Spleen cells (1×10^6 and 5×10^5 cells/well) recovered from vaccinated animals were incubated in the presence of either the β -Gal protein (for IL-2 and IL-4) or a peptide (TPH PARIGL) encompassing its immunodominant MHC class I-restricted epitope (for IFN- γ). Then, the numbers of IFN- γ -, IL-2-, and IL-4-producing cells was determined by ELISPOT. Results are presented as spot forming units per 10^6 cells, which were subtracted from the values obtained from nonstimulated cells. One representative of three independent experiments is shown. The SEM of triplicates is indicated by vertical lines. *C*, Determination of the cytokines secreted by spleen cells recovered from vaccinated animals after *in vitro* re-stimulation with the β -Gal Ag. The amount of cytokines present in supernatant fluids of stimulated cells was measured by FACS using a cytometric bead array (BD Pharmingen). One representative of three independent experiments is shown. *, The obtained results were significantly different ($p < 0.05$) with respect to those from animals immunized with PBS and/or β -Gal alone. \circ , Significantly ($p < 0.05$) different values with respect to results obtained in mice immunized with β -Gal + α -GalCer.



critical feature for a compound aimed at the development of immune interventions, because the activation of DC maturation is recognized as a key event in the stimulation of adaptive immune responses (49). Splenocytes (Fig. 3) and purified NK cells (data not shown) were also efficiently stimulated *in vitro* by α GalCerMPEG. These activities of the pegylated derivative were still dependent on the expression of the CD1d molecule, suggesting that conjugation does not affect the binding features of the active moiety. Additional work also demonstrated that NK cells isolated from mice treated with α GalCerMPEG have stronger cytotoxic activity than those obtained from animals receiving either higher doses of α GalCer or CpG (Fig. 3). It is important to highlight that the stimulatory capacities of α GalCerMPEG on immune cells were maintained intact for at least 2 mo after incubation of a

stock solution (10 μ g/ml in water) at either 4 or 25°C (data not shown).

The excellent performance showed by α GalCerMPEG when tested *in vitro* encouraged us to perform an *in vivo* side-by-side comparison of its adjuvant properties with respect to those of the parental compound α GalCer. The obtained results proved that α GalCerMPEG is a more potent adjuvant than α GalCer when administered by *i.n.* route, even at a 33-fold lower concentration of the active moiety. Coadministration of α GalCerMPEG with the β -Gal protein resulted not only in high titers of β -Gal-specific Abs in serum (i.e., 1:512,000; Fig. 4), but also in the stimulation of more efficient sIgA responses, both at local and remote mucosal effector sites (i.e., nose, lung, and vagina). Significantly increased levels of Ag-specific serum IgG were detected after a single boost

in mice receiving α GalCerMPEG (Fig. 4). The analysis of the IgG subclasses present in sera (i.e., IgG1:IgG2a ratio of 4.6), together with the profile of the cytokines secreted by the splenocytes from vaccinated animals demonstrated that α GalCerMPEG promotes a dominant Th2 response (Fig. 5C). In this regard, BALB/c mice have been described as more prone to mount Th2 responses, whereas stronger Th1 responses are usually observed on C57BL/6 mice (50–53). This feature seems to correlate with the TLR expression pattern on DC and a higher number of CD25⁺ regulatory T cells. However, immunization studies performed using OVA as Ag showed that α GalCerMPEG also promotes Th2 dominant responses in C57BL/6 mice (data not shown).

Interestingly, the use of α GalCerMPEG resulted in a weaker stimulation of Th1-specific and proinflammatory cytokines (i.e., IFN- γ , IL-2, TNF- α , and IL-6) with respect to what was observed in mice receiving α GalCer. The secretion of the anti-inflammatory cytokine IL-10 was also significantly increased in mice receiving α GalCerMPEG. In this context, there are currently attempts to develop agents able to promote endogenous IL-10 production for the treatment of allergies and inflammatory diseases (54, 55). This suggests that α GalCerMPEG might also found an application for the development of immune therapies in this field.

In conclusion, our studies have led to a practical approach for engineering a pegylated derivative of α GalCer, which exhibits improved physical and biological properties. The new compound is water-soluble and retains intact both the specificity for the CD1d receptor and the immune stimulatory properties on immune cells (e.g., DC and NK cells). The α GalCerMPEG also exhibits stronger adjuvant properties than α GalCer, being a superior inducer of sIgA and Th2 responses. The inexpensive nature of the pegylation process, together with the fact that the new derivative is biologically active at 33-fold lower concentrations suggests that its use would be associated with considerable economic benefits. Therefore, the new synthetic derivative α GalCerMPEG represents a promising tool for the development of immune interventions against both infectious and noninfectious diseases.

Acknowledgments

We are particularly grateful to K. Watzke and E. Reinhard for their outstanding technical help. Furthermore, we thank Drs. V. Wray and R. Kraehmer (Celares, Berlin, Germany) for their contribution in the characterization of α GalCerMPEG.

Disclosures

Thomas Ebensen, Michael Morr, Carlos A. Guzman, and the Helmholtz Centre for infection research have a pending patent for the usage of α GalCerMPEG (European community Patent-No.: 05022771.9-2402).

References

- Yamauchi, A., S. Y. Dai, R. Nakagawa, Y. Kashio, H. Abe, S. Katoh, K. Kontani, and M. Hirashima. 2005. [Galectin-9 induces maturation of human monocyte-derived dendritic cells]. *Nihon Rinsho Meneki Gakkai Kaishi* 28: 381–388.
- Cheroute, H., and L. Madakamutil. 2005. Mucosal effector memory T cells: the other side of the coin. *Cell Mol. Life Sci.* 62: 2853–2866.
- Marsland, B. J., N. L. Harris, M. Camberis, M. Kopf, S. M. Hook, and G. Le Gros. 2004. Bystander suppression of allergic airway inflammation by lung resident memory CD8⁺ T cells. *Proc. Natl. Acad. Sci. USA* 101: 6116–6121.
- Schlede, E., T. Maurer, M. Potokar, W. M. Schmidt, K. H. Schulz, R. Roll, and D. Kayser. 1989. A differentiated approach to testing skin sensitization: proposal for a new test guideline skin sensitization. *Arch. Toxicol.* 63: 81–84.
- Nagler-Anderson, C. 2001. Man the barrier: strategic defences in the intestinal mucosa. *Nat. Rev. Immunol.* 1: 59–67.
- Fooks, A. R. 2000. Development of oral vaccines for human use. *Curr. Opin. Mol. Ther.* 2: 80–86.
- Cavallo, F., A. Astolfi, M. Iezzi, F. Cordero, P. L. Lollini, G. Forni, and R. Calogero. 2005. An integrated approach of immunogenomics and bioinformatics to identify new tumor associated antigens (TAA) for mammary cancer immunological prevention. *BMC Bioinformatics* 6(Suppl. 4): S7.
- Guy, B., and N. Burdin. 2005. New adjuvants for parenteral and mucosal vaccines. *Therapie* 60: 235–241.
- Burdin, N., B. Guy, and P. Moingeon. 2004. Immunological foundations to the quest for new vaccine adjuvants. *BioDrugs* 18: 79–93.
- Di Guilmi, A. M., and A. Dessen. 2002. New approaches towards the identification of antibiotic and vaccine targets in *Streptococcus pneumoniae*. *EMBO Rep.* 3: 728–734.
- Teicher, B. A. 2000. Molecular targets and cancer therapeutics: discovery, development and clinical validation. *Drug Resist. Updat.* 3: 67–73.
- Lizotte-Waniewski, M., W. Tawe, D. B. Guiliano, W. Lu, J. Liu, S. A. Williams, and S. Lustigman. 2000. Identification of potential vaccine and drug target candidates by expressed sequence tag analysis and immunoscreening of *Onchocerca volvulus* larval cDNA libraries. *Infect. Immun.* 68: 3491–3501.
- Kobayashi, E., K. Motoki, T. Uchida, H. Fukushima, and Y. Koezuka. 1995. KRN7000, a novel immunomodulator, and its antitumor activities. *Oncol. Res.* 7: 529–534.
- Kawano, T., J. Cui, Y. Koezuka, I. Toura, Y. Kaneko, K. Motoki, H. Ueno, R. Nakagawa, H. Sato, E. Kondo, et al. 1997. CD1d-restricted and TCR-mediated activation of $\nu\alpha$ 14 NKT cells by glycosylceramides. *Science* 278: 1626–1629.
- Sekine, K., H. Fujii, F. Abe, and K. Nishikawa. 2001. Augmentation of death ligand-induced apoptosis by aminopeptidase inhibitors in human solid tumor cell lines. *Int. J. Cancer* 94: 485–491.
- Sharif, S., G. A. Arreaza, P. Zucker, and T. L. Delovitch. 2002. Regulatory natural killer T cells protect against spontaneous and recurrent type 1 diabetes. *Ann. NY Acad. Sci.* 958: 77–88.
- Sharif, S., G. A. Arreaza, P. Zucker, Q. S. Mi, J. Sondhi, O. V. Naidenko, M. Kronenberg, Y. Koezuka, T. L. Delovitch, J. M. Gombert, et al. 2001. Activation of natural killer T cells by α -galactosylceramide treatment prevents the onset and recurrence of autoimmune type 1 diabetes. *Nat. Med.* 7: 1057–1062.
- Singh, A. K., M. T. Wilson, S. Hong, D. Olivares-Villagomez, C. Du, A. K. Stanic, S. Joyce, S. Sriram, Y. Koezuka, and L. Van Kaer. 2001. Natural killer T cell activation protects mice against experimental autoimmune encephalomyelitis. *J. Exp. Med.* 194: 1801–1811.
- Hong, S., M. T. Wilson, I. Serizawa, L. Wu, N. Singh, O. V. Naidenko, T. Miura, T. Haba, D. C. Scherer, J. Wei, et al. 2001. The natural killer T-cell ligand α -galactosylceramide prevents autoimmune diabetes in non-obese diabetic mice. *Nat. Med.* 7: 1052–1056.
- Teige, A., I. Teige, S. Lavasani, R. Bockermann, E. Mondoc, R. Holmdahl, and S. Issazadeh-Navikas. 2004. CD1-dependent regulation of chronic central nervous system inflammation in experimental autoimmune encephalomyelitis. *J. Immunol.* 172: 186–194.
- van Dommelen, S. L., H. A. Tabarias, M. J. Smyth, and M. A. Degli-Esposti. 2003. Activation of natural killer (NK) T cells during murine cytomegalovirus infection enhances the antiviral response mediated by NK cells. *J. Virol.* 77: 1877–1884.
- Furlan, R., A. Bergami, D. Cantarella, E. Brambilla, M. Taniguchi, P. Dellabona, G. Casorati, and G. Martino. 2003. Activation of invariant NKT cells by α GalCer administration protects mice from MOG35–55-induced EAE: critical roles for administration route and IFN- γ . *Eur. J. Immunol.* 33: 1830–1838.
- Gonzalez-Aseguinolaza, G., L. Van Kaer, C. C. Bergmann, J. M. Wilson, J. Schmieg, M. Kronenberg, T. Nakayama, M. Taniguchi, Y. Koezuka, and M. Tsuji. 2002. Natural killer T cell ligand α -galactosylceramide enhances protective immunity induced by malaria vaccines. *J. Exp. Med.* 195: 617–624.
- Gonzalez-Aseguinolaza, G., C. de Oliveira, M. Tomaska, S. Hong, O. Bruna-Romero, T. Nakayama, M. Taniguchi, A. Bendelac, L. Van Kaer, Y. Koezuka, and M. Tsuji. 2000. α -Galactosylceramide-activated $\nu\alpha$ 14 natural killer T cells mediate protection against murine malaria. *Proc. Natl. Acad. Sci. USA* 97: 8461–8466.
- Shin-ichiro, F., K. Shimizu, C. Smith, L. Bonifaz, and R. M. Steinman. 2003. Activation of natural killer T cells by α -galactosylceramide rapidly induces the full maturation of dendritic cells in vivo and thereby acts as an adjuvant for combined CD4 and CD8 T cell immunity to a coadministered protein. *J. Exp. Med.* 198: 267–279.
- Kopecky, E. M., S. Greinstetter, I. Pabinger, A. Buchacher, J. Romisch, and A. Jungbauer. 2006. Effect of oriented or random PEGylation on bioactivity of a factor VIII inhibitor blocking peptide. *Biotechnol. Bioeng.* 93: 647–655.
- Frokjaer, S., and D. E. Otzen. 2005. Protein drug stability: a formulation challenge. *Nat. Rev. Drug Discov.* 4: 298–306.
- Deckert, P. M., A. Jungbluth, N. Montalto, M. A. Clark, R. D. Finn, C. Williams, Jr., E. C. Richards, K. S. Panageas, L. J. Old, and S. Welt. 2000. Pharmacokinetics and microdistribution of polyethylene glycol-modified humanized A33 antibody targeting colon cancer xenografts. *Int. J. Cancer* 87: 382–390.
- Bradley, M. P., L. A. Hinds, and P. H. Bird. 1997. A bait-delivered immun contraceptive vaccine for the European red fox (*Vulpes vulpes*) by the year 2002? *Reprod. Fertil. Dev.* 9: 111–116.
- Hessel, E. M., M. Chu, J. O. Lizcano, B. Chang, N. Herman, S. A. Kell, M. Wills-Karp, and R. L. Coffman. 2005. Immunostimulatory oligonucleotides block allergic airway inflammation by inhibiting Th2 cell activation and IgE-mediated cytokine induction. *J. Exp. Med.* 202: 1563–1573.
- Molineux, G. 2003. Pegylation: engineering improved biopharmaceuticals for oncology. *Pharmacotherapy* 23: 3S–8S.
- Guiotto, A., M. Pozzobon, M. Canevari, R. Manganelli, M. Scarin, and F. M. Veronese. 2003. PEGylation of the antimicrobial peptide nisin A: problems and perspectives. *Farmaco* 58: 45–50.
- DeSantis, G., and J. B. Jones. 1999. Chemical modification of enzymes for enhanced functionality. *Curr. Opin. Biotechnol.* 10: 324–330.
- Pomroy, N. C., and C. M. Deber. 1998. Solubilization of hydrophobic peptides by reversible cysteine PEGylation. *Biochem. Biophys. Res. Commun.* 245: 618–621.

35. Katre, N. V. 1990. Immunogenicity of recombinant IL-2 modified by covalent attachment of polyethylene glycol. *J. Immunol.* 144: 209–213.
36. Zhou, S., X. Liao, X. Li, X. Deng, and H. Li. 2003. Poly-D,L-lactide-co-poly-(ethylene glycol) microspheres as potential vaccine delivery systems. *J. Control Release* 86: 195–205.
37. Ortaldo, J. R., H. A. Young, R. T. Winkler-Pickett, E. W. Bere, Jr., W. J. Murphy, and R. H. Wiltrout. 2004. Dissociation of NKT stimulation, cytokine induction, and NK activation in vivo by the use of distinct TCR-binding ceramides. *J. Immunol.* 172: 943–953.
38. De Vendittis, E., G. Palumbo, G. Parlato, and V. Bocchini. 1981. A fluorimetric method for the estimation of the critical micelle concentration of surfactants. *Anal. Biochem.* 115: 278–286.
39. Nerenberg, S. T., C. Ganger, and L. DeMarco. 1971. Rapid fluorescent “staining” of nondenatured protein bands in agar and polyacrylamide gels. *Anal. Biochem.* 43: 564–574.
40. Ebensen, T., S. Paukner, C. Link, P. Kudela, C. de Domenico, W. Lubitz, and C. A. Guzman. 2004. Bacterial ghosts are an efficient delivery system for DNA vaccines. *J. Immunol.* 172: 6858–6865.
41. Borsutzky, S., V. Fiorelli, T. Ebensen, A. Tripiciano, F. Rharbaoui, A. Scoglio, C. Link, F. Nappi, M. Morr, S. Butto, et al. 2003. Efficient mucosal delivery of the HIV-1 Tat protein using the synthetic lipopeptide MALP-2 as adjuvant. *Eur. J. Immunol.* 33: 1548–1556.
42. Giaccone, G., C. Punt, Y. Ando, R. Ruijter, N. Nishi, M. Peters, B. von Blomberg, R. Scheper, H. van der Vliet, A. van den Eertwegh, et al. 2002. A phase I study of the natural killer T-cell ligand α -galactosylceramide (KRN7000) in patients with solid tumors. *Clin. Cancer Res.* 8: 3702–3709.
43. Borsutzky, S., T. Ebensen, C. Link, P. D. Becker, V. Fiorelli, A. Cafaro, B. Ensoli, and C. A. Guzman. 2006. Efficient systemic and mucosal responses against the HIV-1 Tat protein by prime/boost vaccination using the lipopeptide MALP-2 as adjuvant. *Vaccine* 24: 2049–2056.
44. Godfrey, D. I., and M. Kronenberg. 2004. Going both ways: immune regulation via CD1d-dependent NKT cells. *J. Clin. Invest.* 114: 1379–1388.
45. Ko, S. Y., H. J. Ko, W. S. Chang, S. H. Park, M. N. Kweon, and C. Y. Kang. 2005. α -Galactosylceramide can act as a nasal vaccine adjuvant inducing protective immune responses against viral infection and tumor. *J. Immunol.* 175: 3309–3317.
46. Ishikawa, A., S. Motohashi, E. Ishikawa, H. Fuchida, K. Higashino, M. Otsuji, T. Iizasa, T. Nakayama, M. Taniguchi, and T. Fujisawa. 2005. A phase I study of α -galactosylceramide (KRN7000)-pulsed dendritic cells in patients with advanced and recurrent non-small cell lung cancer. *Clin. Cancer Res.* 11: 1910–1917.
47. Chang, D. H., K. Osman, J. Connolly, A. Kukreja, J. Krasovsky, M. Pack, A. Hutchinson, M. Geller, N. Liu, R. Annable, et al. 2005. Sustained expansion of NKT cells and antigen-specific T cells after injection of α -galactosyl-ceramide loaded mature dendritic cells in cancer patients. *J. Exp. Med.* 201: 1503–1517.
48. Nieda, M., M. Okai, A. Tazbirkova, H. Lin, A. Yamaura, K. Ide, R. Abraham, T. Juji, D. Macfarlane, and A. J. Nicol. 2004. Therapeutic activation of $V\alpha 24^+V\beta 11^+$ NKT cells in human subjects results in highly coordinated secondary activation of acquired and innate immunity. *Blood* 103: 383–389.
49. Banchereau, J., C. Bidaud, A. C. Fluckiger, L. Galibert, P. Garrone, F. Malisan, and D. Pandrau. 1993. Effects of interleukin 4 on human B-cell growth and differentiation. *Res. Immunol.* 144: 601–605.
50. Gemmell, E., C. L. Carter, P. S. Bird, and G. J. Seymour. 2002. Genetic dependence of the specific T-cell cytokine response to *Porphyromonas gingivalis* in mice. *J. Periodontol.* 73: 591–596.
51. Gemmell, E., K. E. Drysdale, and G. J. Seymour. 2006. Gene expression in splenic CD4 and CD8 cells from BALB/c mice immunized with *Porphyromonas gingivalis*. *J. Periodontol.* 77: 622–633.
52. Gemmell, E., C. Sernia, D. A. Grieco, P. S. Bird, C. J. Allen, and G. J. Seymour. 2001. Genetic variation in the recognition of *Porphyromonas gingivalis* antigens in mice. *Oral Microbiol. Immunol.* 16: 129–135.
53. Gemmell, E., T. A. Winning, D. A. Grieco, P. S. Bird, and G. J. Seymour. 2000. The influence of genetic variation on the splenic T cell cytokine and specific serum antibody responses to *Porphyromonas gingivalis* in mice. *J. Periodontol.* 71: 1130–1138.
54. Urry, Z., E. Xystrakis, and C. M. Hawrylowicz. 2006. Interleukin-10-secreting regulatory T cells in allergy and asthma. *Curr. Allergy Asthma Rep.* 6: 363–371.
55. Zhou, X., P. Schmidtke, F. Zepp, and C. U. Meyer. 2005. Boosting interleukin-10 production: therapeutic effects and mechanisms. *Curr. Drug Targets Immune Endocr. Metabol. Disord.* 5: 465–475.